Compared to anti-PD-L1 monotherapy, the combination of anti-PD-L1 and anti-CTLA-4 antibodies did not alter tumor eradication in the mouse melanoma model, despite an increase in highly motile T cells in the peri-tumoral area [148]. Here, CTLA4 is linked to neoplasm.